Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006890 · ClinicalTrials.gov registry record · Phase 2
Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
A Phase 2 study, sponsored by NCIC Clinical Trials Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
NCT00006890 is a Phase 2 study that has completed, run by NCIC Clinical Trials Group. The registered enrollment target is 67 participants.
The verdict
NCT00006890, a Phase 2 study, has completed, sponsored by NCIC Clinical Trials Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
Study Summary
RATIONALE: Thalidomide may stop the growth of multiple myeloma by stopping blood flow to the tumor. Prednisone may be effective in preventing relapse of multiple myeloma. PURPOSE: Randomized phase II trial to compare the effectiveness of two doses of thalidomide combined with prednisone following peripheral stem cell transplantation in treating patients who have multiple myeloma.
Interventions
- DRUG prednisone
- DRUG thalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2000-07-12 |
| Est. Completion | 2008-12-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006890
The ClinicalTrials.gov registry entry for NCT00006890 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NCIC Clinical Trials Group, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which prednisone is the first listed.
NCT00006890 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006890 about?
NCT00006890 is a clinical study titled "Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma". RATIONALE: Thalidomide may stop the growth of multiple myeloma by stopping blood flow to the tumor. Prednisone may be effective in preventing relapse of multiple myeloma. PURPOSE: Randomized phase II trial to compare the effectiveness of two doses of thalidomide combined with prednisone following p...
What is the current status of trial NCT00006890?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2000-07-12. Estimated completion is 2008-12-15.
What interventions are being tested in trial NCT00006890?
The interventions under investigation include: prednisone (DRUG), thalidomide (DRUG).
Who is sponsoring clinical trial NCT00006890?
This trial is sponsored by NCIC Clinical Trials Group, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.